SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia
The omaveloxolone appropriate utilization consensus delivers a tightly controlled framework for using Skyclarys in Friedreich’s ataxia, restricting initiation and discontinuation decisions to two specialized Dutch centers. By combining validated functional scales with strict safety thresholds and...
Conditional Adoption Pathways for Endometriosis Diagnostics
The introduction of conditional adoption pathways for endometriosis offers a structured route to faster diagnosis for the millions of women facing four-to-ten-year delays within the NHS. N...
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care
Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...